ATS Swings to $5M Loss, Abandons FY2027 Growth and Margin Targets on Tariff Delays
ATS is trading near its 52-week low of $17.15 (11% above the low).
Summary
ATS posted a Q2 FY2027 net loss of $5.0 million (5 cents a share) versus $33.6 million of net income a year ago, with revenues down 8.6% to $665.8 million and adjusted EPS at 27 cents from 45 cents. The bigger blow is guidance: management scrapped its prior fiscal 2027 goals of modest revenue growth and 50-75 basis points of margin expansion, citing delayed non-life sciences order bookings tied to Section 338 tariffs on Canadian-made packaging equipment and the time backlog takes to convert. Adjusted EBITDA fell 22.2% to $80.7 million and the adjusted operating margin dropped to 8.6% from 10.9%. Offsetting that, order bookings rose 12.7% to $827 million on record life sciences backlog, and the U.S. eased Section 338 tariffs at the end of October, removing the impact on most covered products. Q3 revenue is guided to $640-680 million, and the Fixed Cost Transformation Program targets $65-75 million of annualized savings with 300-400 headcount reductions. ATS recorded $21.3 million of restructuring costs in Q2 FY2027, about half tied to the Fixed Cost Transformation Program, and expects to cut roughly 300 to 400 workers including subcontractors. The 8:30 a.m. ET call today will be the first chance to press management on how quickly bookings convert.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — ATS recorded $21.3 million of restructuring costs in Q2 FY2027, about half tied to the Fixed Cost Transformation Program, and expects to cut roughly 300 to 400 workers including subcontractors.
At the time of this announcement, ATS was trading at $18.96 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $17.15 to $35.82. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.